Sexuality is an integral part of gender identity, self-image, and overall well-being. Sexual dysfunctions present in all cultures and ethnicities around the world. Sexual problems have an especially high prevalence among patients with psychiatric syndromes -- yet, in recent years, the field of psychiatry has shifted away from the treatment of sexual disorders. Clinical Manual of Sexual Disorders is the first comprehensive text in decades to address the management and treatment of sexual dysfunctions and disorders. Using a conceptual model that incorporates biological, psychological, and cultural interventions as its guiding principle, the book explores and evaluates the epidemiology of sexual disorders and paraphilias, sexual dysfunctions with comorbid psychiatric disorders, sexual problems associated with various medications, and sexual disorders in specific patient populations. Written by 25 contributing clinical specialists from around the world, the text combines conceptual shifts within the field of human sexuality with the latest research findings into a practical three-part volume. The first four chapters cover general areas relevant to the clinical understanding of human sexuality and sexual dysfunctions within the frame of psychiatry. The second part of the book outlines the major sexual dysfunctions, including male erectile disorder, female arousal disorder, premature ejaculation, and paraphilias. And the final chapters address the management of sexual issues in two unique patient populations that are often neglected in other textbooks -- children and adolescents and older adults. The book includes several unique features to further enhance learner retention Tables, charts, figures, and illustrations to enhance the reading material Evaluations, questionnaires and other patient materials Take-away points on key clinical issues at the end of each chapter Case examples from the authors' own practices References for further reading Restoration of sexual function can improve the quality of life for many individuals with and without psychiatric disorders, making recognition and treatment of sexual problems of utmost importance to any general psychiatric practice. As the only text of its kind, Clinical Manual of Sexual Disorders provides a concise, clinically-oriented biopsychosocial guide to the management and treatment of sexual dysfunction that is appropriate for all psychiatric, clinical, and educational settings.

Leading clinicians and basic scientists comprehensively survey for the general practitioner the background, diagnostic tools, associated conditions, causes, and treatments of erectile dysfunction. Here the busy practitioner will find concise and useful information on the anatomy and physiology of erectile function and dysfunction, ejaculatory disorders, Peyronie's disease, and priapism-as well as a chapter on female sexual dysfunction-in addition to thorough chapters on diagnosis and treatment.

Experts provide specific methodologies for clinicians working with recovering alcoholics and their families. This landmark study of sexual issues in alcoholism treatment addresses impotence in male alcoholics, the sexual dynamics of the client-counselor relationship, homosexual alcoholics, and many other important issues.

Experts provide specific methodologies for clinicians working with recovering alcoholics and their families. This landmark study of sexual issues in alcoholism treatment addresses impotence in male alcoholics, the sexual dynamics of the client-counselor relationship, homosexual alcoholics, and many other important issues.

For the generation that reached sexual maturity in the 1960s, the “pill” became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society’s perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought “this will change everything” and it clearly has—changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.